Amwill Health Care opened lower at ₹41.75, compared with its previous close of ₹43.50. In the last trading session on 12 Nov 2026, the stock traded between ₹41.75 and ₹42.59, with an average traded price of ₹42.38. It showed a downward intraday trend.
An investment of ₹10,000 made 2 years ago in Amwill Health Care is now worth
₹ 4,567.00
Resulting in a loss of
₹ 5,433.00 (54.33%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.91 (-2.09%)
Day High
₹42.59
Day Low
₹41.75
Day Open
₹41.75
Prev Close
₹43.50
Volume
4,800
Value Traded
₹0.02 Cr
1W Return
1.84%
1M Return
-0.95%
3M Return
-0.02%
6M Return
22.03%
1Y Return
-14.84%
Market Cap (₹ Cr.)
85
PE Ratio
7.60
PB Ratio
1.08
Dividend Yield
1.15%
ROE
14.17%
ROCE
19.00%
Book Value (₹)
40.28
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
1.84%
6 Weeks
-
1 Month
-0.95%
3 Months
-0.02%
9 Months
16.68%
No data available.
Amwill Health Care commits ₹3 crore to Nippon India credit AIF
Committed ₹3 crore to Nippon India Credit Opportunities AIF Scheme II. Investment funded entirely through internal accruals. Capital deployment scheduled in tranches following August 2026 approval. No related party involvement in the chosen Alternative Investment Fund.
8 days agoAmwill Health Care Q2FY27 Results: Net profit falls 5% YoY to ₹367.39 lakh
Declared interim dividend of ₹0.50 per share for FY27. Net profit fell 5.2% YoY to ₹367.39 lakh in H1FY27. Revenue from operations grew 6.7% YoY to ₹2,262.86 lakh. Record date fixed for October 30, 2026. Other expenses rose significantly, impacting margins.
20 days agoAmwill Health Care secures CDSCO license for FoliColor imports
Amwill Health Care obtained CDSCO import license for FoliColor hair colour. Registration certificate RC/COS-007631 valid until October 7, 2031. License enables commercial sale of Black variant oxidative hair colour. Approval is a new grant; supplier is not a related party.
1mo agoAmwill Health Care approves ₹3 crore investment in two AIF schemes
Amwill Health Care approved ₹3 crore total investment in two AIF schemes. ₹1.50 crore allocated to Vivriti Vihaan Trust for long-term growth. ₹1.50 crore allocated to Neo Income Plus Fund III for operational support. Investments funded via internal accruals with no related party involvement.
1mo agoAmwill Health Care shareholders approve FY26 accounts, reappoint MDs
Amwill Health Care Limited held its 9th AGM on August 14, 2026, where shareholders approved FY26 financials and dividends. The board saw the reappointment of Ms. Sapna Parmar as a director and Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors. No adverse remarks were noted in the secretarial audit report.
3mo agoAmwill Health Care sets ₹33cr investment limits across assets
Amwill Health Care Limited approved a ₹33 crore investment limit across debt, equity, and alternative assets on August 08, 2026. The strategy includes ₹15 crore for private credit/AIFs, ₹10 crore for government securities/NCDs, and smaller allocations for equity and mutual funds, aiming to optimize surplus cash returns.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,898.50 | +0.72% | ₹4,55,513.74 | 41.20 | +9.61% | |
| ₹11,506.00 | +0.18% | ₹3,05,448.15 | 90.40 | +76.47% | |
| ₹4,689.50 | -0.80% | ₹1,78,373.51 | 85.50 | +22.61% | |
| ₹2,434.80 | +1.45% | ₹1,31,555.22 | 97.10 | +146.13% | |
| ₹1,204.60 | -0.12% | ₹1,20,159.31 | 28.00 | +26.61% | |
| ₹1,389.60 | +0.22% | ₹1,15,987.17 | 42.00 | +13.01% | |
| ₹1,409.00 | +0.05% | ₹1,13,827.26 | 39.90 | -7.26% | |
| ₹2,666.70 | +1.06% | ₹1,10,146.73 | 48.10 | +17.48% | |
| ₹1,815.40 | +0.45% | ₹1,04,454.10 | 26.00 | +53.38% | |
| ₹2,020.80 | +0.29% | ₹92,409.16 | 17.60 | -0.64% | |
| ₹2,643.30 | -0.62% | ₹74,600.45 | 51.60 | +43.05% | |
| ₹5,190.00 | -2.11% | ₹62,054.24 | 30.50 | -10.01% |
An investment of ₹10,000 made 2 years ago in Amwill Health Care is now worth
₹ 4,567.00
Resulting in a loss of
₹ 5,433.00 (54.33%)
Note: Past profits do not guarantee future returns.
